RU2020129401A3 - - Google Patents

Download PDF

Info

Publication number
RU2020129401A3
RU2020129401A3 RU2020129401A RU2020129401A RU2020129401A3 RU 2020129401 A3 RU2020129401 A3 RU 2020129401A3 RU 2020129401 A RU2020129401 A RU 2020129401A RU 2020129401 A RU2020129401 A RU 2020129401A RU 2020129401 A3 RU2020129401 A3 RU 2020129401A3
Authority
RU
Russia
Application number
RU2020129401A
Other languages
Russian (ru)
Other versions
RU2020129401A (ru
RU2772132C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18194549.4A external-priority patent/EP3623382A1/en
Application filed filed Critical
Publication of RU2020129401A publication Critical patent/RU2020129401A/ru
Publication of RU2020129401A3 publication Critical patent/RU2020129401A3/ru
Application granted granted Critical
Publication of RU2772132C2 publication Critical patent/RU2772132C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243Colony Stimulating Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2020129401A 2018-02-22 2019-02-22 Лиганды гм-ксф или рецептора гм-ксф для применения при лечении гемобластоза у пациента, перенесшего алло-тгк RU2772132C2 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18158169 2018-02-22
EP18158169.5 2018-02-22
EP18189562 2018-08-17
EP18189562.4 2018-08-17
EP18194549.4 2018-09-14
EP18194549.4A EP3623382A1 (en) 2018-09-14 2018-09-14 Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US16/269,572 US11655293B2 (en) 2018-02-22 2019-02-07 Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US16269572 2019-02-07
PCT/EP2019/054493 WO2019162472A1 (en) 2018-02-22 2019-02-22 Ligands to gm-csf or gm-csf-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-hct

Publications (3)

Publication Number Publication Date
RU2020129401A RU2020129401A (ru) 2022-03-22
RU2020129401A3 true RU2020129401A3 (enExample) 2022-03-22
RU2772132C2 RU2772132C2 (ru) 2022-05-18

Family

ID=

Also Published As

Publication number Publication date
JP7278296B2 (ja) 2023-05-19
BR112020017253A2 (pt) 2020-12-22
MX2020008792A (es) 2020-10-14
RU2020129401A (ru) 2022-03-22
JP2021514368A (ja) 2021-06-10
US20210070851A1 (en) 2021-03-11
US11655293B2 (en) 2023-05-23
US20190256587A1 (en) 2019-08-22
MA51893A (fr) 2020-12-30
KR20200123434A (ko) 2020-10-29
CN111886248B (zh) 2025-03-04
EP3755715A1 (en) 2020-12-30
CA3091536A1 (en) 2019-08-29
WO2019162472A1 (en) 2019-08-29
US20230340100A1 (en) 2023-10-26
MX2023001357A (es) 2023-02-27
US12384839B2 (en) 2025-08-12
AU2019224550A1 (en) 2020-09-17
CN111886248A (zh) 2020-11-03

Similar Documents

Publication Publication Date Title
BR112021012222A2 (enExample)
BR122022006221A2 (enExample)
BR122022015534A2 (enExample)
BR122022002096A2 (enExample)
AT524834A2 (enExample)
AT524874A5 (enExample)
AU2018438767B1 (enExample)
AT524266A2 (enExample)
AT524961A5 (enExample)
BR122022005529A2 (enExample)
BR122022016585A2 (enExample)
BR112020012832A2 (enExample)
BR202018071071U8 (enExample)
BR102018070765A2 (enExample)
BR102018016915A2 (enExample)
BE2018C025I2 (enExample)
BR112020025288A2 (enExample)
BR202018008879U2 (enExample)
BR202018007669U2 (enExample)
BR102018007062A2 (enExample)
BR202018006247U2 (enExample)
BR202018004136U2 (enExample)
BR202018002487U2 (enExample)
BR202018002069U2 (enExample)
CN304434040S (enExample)